The journal Kemivärlden Biotech features an article on Ventac portfolio company, Idogen, highlighting the company’s work on the development of tolerogenic vaccines. To read the article (in Swedish), please follow this link.
Our partners author several articles and analyses in science and industry journals.
Idogen’s CEO and partner in Ventac Partners, Lars Hedbys gives an interview in the Medicon Village newsletter discussing collaboration opportunities in the area. To read the article (in Swedish), please follow this link.
Ventac Partner Kostas Alevizopoulos authors article entitled “How will specialty drugs affect the global healthcare industry in 2015?” To read the article, please follow this link.